Prolacta Bioscience applauds passage of New York legislation expanding insurance coverage for human milk-based nutritional products
Type: Press Releases
Topic(s): Advocacy Company
Prolacta Bioscience applauds new California state law expanding access to donor human milk for fragile infants
Type: Press Releases
Topic(s): Company Necrotizing Entercolitis (NEC)
More than 50% of level III & IV NICUs in U.S. used Prolacta's 100% human milk-based products to help reduce Necrotizing Enterocolitis (NEC) in the smallest premature infants in 2024
Type: Press Releases
Topic(s): Company Necrotizing Entercolitis (NEC)
Prolacta Bioscience applauds passage of the maternal health bill in Massachusetts
Type: Press Releases
Topic(s): Advocacy
Working to address equity in premature nutrition, National Black Nurses Association and Prolacta Bioscience support H.R. 7141
Type: Press Releases
Topic(s): Cost Savings / Cost Effectiveness Early Fortification Growth Product
Preterm infant study finds proactive use of Prolact CR cream improves growth and reduces NICU costs
Type: Press Releases
Topic(s): Cost Savings / Cost Effectiveness Early Fortification Growth Product
Prolacta Bioscience demonstrates leadership in human milk science with history of voluntarily reviewing health claims with the FDA
Type: Press Releases
Topic(s): Company
Human milk-based fortifiers cut mortality rate by 50% in preterm infants, independent study shows
Type: Press Releases
Topic(s): Clinical Studies Mortality
Study shows exclusive human milk diet benefits term infants post-gastroschisis repair; Data to be presented at ESPGHAN 2024 meeting
Type: Press Releases
Topic(s): Clinical Studies Conferences and Events
Not finding the reference you’re looking for?
Use our main search field or email us at info@prolacta.com